Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Motilal Oswal Securities Ltd.
$69.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biocon Ltd and Mylan Inc receive Indian regulatory nod to market breast cancer drug


Tuesday, 26 Nov 2013 04:03am EST 

Biocon Ltd:Says it has received Marketing Authorization from the Drugs Controller General of India (DCGI) for its biosimilar Trastuzumab being developed jointly with Mylan Inc for the treatment of Her 2+ metastatic breast cancer.The biosimilar Trastuzumab will be marketed in India under the brand name of 'CANMAb' by Biocon and is expected to be available to India patients in Q4 FY 14. 

Company Quote

474.1
0.6 +0.13%
22 Aug 2014